The PulseCalendarExplorerLongevity Clinics MapLongevity Investors MapWearables & Nearables MapAbout

Back to Longevity News

Longevity News

Gan & Lee Pharmaceuticals Achieves Significant Progress in Its Dual Pipeline for Metabolic Diseases -- Weekly Insulin Ludefen (GZR4) Meets Primary Endpoint in Phase III Clinical Trial in China; Bofanglutide Meets Primary Endpoints in Phase III Weight Loss Study in China and Phase II Study in the U.S.

Source: PR Newswire • Published: 12 Jun 2026, 12:00

Gan & Lee Pharmaceuticals Achieves Significant Progress in Its Dual Pipeline for Metabolic Diseases -- Weekly Insulin Ludefen (GZR4) Meets Primary Endpoint in Phase III Clinical Trial in China; Bofanglutide Meets Primary Endpoints in Phase III Weight Loss Study in China and Phase II Study in the U.S.

Diabetes and obesity pipeline developments from a pharmaceutical company. Read a concise update on recent clinical milestones and expanding international studies.

Key Takeaways
  • News provided by Gan & Lee Pharmaceuticals Jun 12
  • Drug's pivotal Phase III clinical trial in China, SUPER-3, recently met its pre-specified primary endpoint
  • Study enrolled 596 adults with type 2 diabetes (T2DM)
Read Original Source